Company Overview - Clene Inc. (NASDAQ: CLNN) is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases, particularly through nanotherapeutics [1] - The company competes with other biotech firms such as Biogen and Novartis in the same therapeutic area [1] Shareholder Activity - On January 7, 2026, significant shareholder Ugwumba Chidozie sold 3,938 shares at $6.29 each, following a previous sale of 4,138 shares on December 30 at $6.03, totaling approximately $24,952 [2] - After the January 7 transaction, Chidozie holds 753,562 shares, a decrease from 783,590 shares held after the December 30 sale, but he remains a major shareholder with holdings valued at around $4.7 million [3] Stock Performance - The current price of CLNN is $6.28, reflecting a 2.28% increase, with intraday fluctuations between $6.06 and $6.56 [4] - Over the past year, CLNN's stock price ranged from a high of $13.50 to a low of $2.28, and the company's market capitalization is approximately $58.4 million [4] - The trading volume on the NASDAQ exchange is 51,957 shares [4]